









Markets
/
Stocks
/
nasdaq-xbit
/

XBiotech Inc

XBIT

2.720USD

-0.040-1.45%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

82.93MMarket Cap

LossP/E TTM



XBiotech Inc

2.720

-0.040-1.45%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

250 / 506

Overall Ranking

408 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 17.12.

Overvalued

The company’s latest PE is -2.94, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 14.95M shares, decreasing 8.61% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 945.40K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.31.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.88, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

6.88

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

4.69

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.70

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

5.00

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.99, which is 5.80% below the recent high of -3.16 and -90.65% above the recent low of -5.69.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 250/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.58, which is equal to the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 3.38 and the support level at 2.36, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.58

Change

-0.07

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.060

Sell

RSI(14)

37.978

Neutral

STOCH(KDJ)(9,3,3)

35.748

Buy

ATR(14)

0.151

Low Volatility

CCI(14)

-47.966

Neutral

Williams %R

79.681

Sell

TRIX(12,20)

-0.553

Sell

StochRSI(14)

72.914

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

2.712

Buy

MA10

2.746

Sell

MA20

2.964

Sell

MA50

2.973

Sell

MA100

2.926

Sell

MA200

3.411

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 49.05%, representing a quarter-over-quarter decrease of 2.01%. The largest institutional shareholder is The Vanguard, holding a total of 945.40K shares, representing 3.10% of shares outstanding, with 11.21% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Gut (Thomas)

3.91M

Simard (John)

3.82M

McKenzie (Thorpe W)

2.70M

-0.60%

The Vanguard Group, Inc.

Star Investors

1.06M

-0.17%

Millennium Management LLC

82.36K

-68.75%

BlackRock Institutional Trust Company, N.A.

1.15M

-1.32%

Geode Capital Management, L.L.C.

461.23K

+1.47%

Waldin (Jan-Paul)

200.24K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.09, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.87. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.